This project will examine how the use of Jubbonti and Wyost, two biosimilar medications recently launched in Canada, can help reduce healthcare costs while maintaining access to high-quality treatment. These biosimilars are approved alternatives to a widely used biologic drug for treating osteoporosis and bone complications related to cancer. Working with the pharmaceutical company Sandoz, […]
Read More